Research Article
Prevalence of HIV-Associated Metabolic Abnormalities among Patients Taking First-Line Antiretroviral Therapy in Uganda
Table 3
Prevalence of dyslipidemia and hyperglycemia in HIV-infected patients according to stavudine- and zidovudine-containing regimens.
| | | Stavudine | Zidovudine | Total | | | Lipid abnormalities | | | | value | | | (%) | (%) | (%) | |
| | Total cholesterol |
|
|
|
| | Borderline | 58 (27.9) | 48 (22.3) | 106 (25.1) | 0.018 | | High | 35 (16.8) | 24 (11.2) | 59 (14.0) | | LDL-cholesterol |
| | | | | Borderline | 29 (13.9) | 17 (7.9) | 46 (10.9) | 0.013 | | High | 22 (10.6) | 15 (7.0) | 37 (44.6) | | Triglycerides | | | | | | Borderline | 40 (19.2) | 31 (14.4) | 71 (16.8) | 0.025 | | High | 19 (9.1) | 10 (4.7) | 29 (6.9) | | HDL-cholesterol |
|
|
|
| | Borderline | 147 (70.7) | 87 (40.5) | 234 (55.3) | 0.001
| | Low | 12 (5.8) | 7 (3.3) | 19 (4.5) | | Dyslipidemia | | | | | | Borderline | 190 (91.4) | 155 (72.1) | 345 (81.6) | 0.001
| | Overt | 46 (22.1) | 34 (15.8) | 80 (18.9) | | Hyperglycemia | | | | | | Borderline | 23 (11.1) | 38 (17.7) | 61 (14.4) | | | Overt | 6 (2.9) | 11 (5.1) | 17 (4.0) | |
|
|
TC: total cholesterol; LDL: low-density lipoprotein; HDL: high-density lipoprotein.
|
